Details revealed behind psoriasis and wound repair: 2 sides of the same coin

June 21, 2012

The dynamic properties of the skin that take charge when a cut or scrape needs healing are critical for maintaining the skin's integrity, but if they get out of control, they can cause problems in the form of psoriasis and other skin disorders. Researchers reporting on June 21st in the Cell Press journal Immunity have now uncovered key information on how cells are stimulated to multiply during these processes. The information might be used to develop new treatments for psoriasis and hard-to-heal skin wounds.

For their studies, the scientists analyzed skin biopsies from individuals with and without psoriasis as well as the skin of mice with wounds on their backs and mice with psoriasis-like pathology. They found that a molecule called regenerating islet-derived protein 3-alpha (REG3A) is highly expressed in skin cells during psoriasis and wound repair, but not under normal skin conditions. Blocking REG3A delayed wound healing and cleared up psoriasis-like pathology in mice. The researchers also revealed the cascade of molecules that appear to act in conjunction with REG3A. Specifically, interleukin-17 (IL-17) binds to the IL-17 receptor A on skin cells and causes REG3A to be expressed; then REG3A binds to the exostosin-like 3 protein within cells, which activates certain enzymes that coax the cells to continue multiplying.

Previous research indicates that IL-17 is abundant in patients with psoriasis, and treatments that target the IL-17 pathway lessen their symptoms. "REG3A is stimulated by proteins known to be important to the pathogenesis of psoriasis. Therefore, REG3A appears to be the link between these proteins and the excess proliferation of skin cells that occurs in psoriasis," says first and corresponding author Dr. Yuping Lai, from the East China Normal University.

The findings offer potential targets for therapy. "A drug that inhibits REG3A would represent a more targeted way to treat psoriasis and avoid the systemic immunosuppression found with current therapy. Also, a drug that stimulates or mimics REG3A could be used to improve wound healing," says senior author Dr. Richard Gallo, from the University of California, San Diego.

Somewhat mysteriously, REG3A is also secreted by cells within the intestines and internal organs, where it has antimicrobial properties.
Lai et al.: "The Antimicrobial Protein REG3A Regulates Keratinocyte Proliferation and Differentiation after Skin Injury."

Cell Press

Related Psoriasis Articles from Brightsurf:

Most psoriasis patients taking immunosuppressants survive COVID-19
Patients with psoriasis who are taking drugs that affect their immune system have high rates of survival from COVID-19.

Getting under the skin of psoriasis
Psoriasis afflicts millions of people worldwide, but treatments are limited to small molecules like steroids, which can cause skin thinning and lose their effectiveness over time.

Psoriasis patients' mental health is more than skin-deep
A new study from Umeå University, Sweden, shows that other somatic diseases have even more impact on patients' mental health than their skin symptoms, highlighting the importance of holistic patient care.

Psoriasis: Towards a novel therapeutic approach
Researchers at the Université libre de Bruxelles (ULB) and the Department of Dermatology of the Erasme hospital uncover the importance of VEGFA signaling in the epidermis to mediate psoriasis development.

Insights into psoriasis suggest a new treatment target
Investigators from Brigham and Women's Hospital and the Harvard Stem Cell Institute have uncovered a novel pathway that may explain why skin thickens in psoriasis and suggests new strategies for developing therapies for the condition.

Psoriasis onset determines if psoriatic arthritis patients develop arthritis or psoriasis first
In a new study presented at the 2019 ACR/ARP Annual Meeting, researchers found the age of psoriasis onset determines whether arthritis or psoriasis starts first in people with psoriatic arthritis.

Study: Some biologic treatments for psoriasis may be safer for patients
In the largest study of its kind, Erica D. Dommasch, M.D., M.P.H., a dermatologist in the Department of Dermatology at BIDMC, and colleagues found a decreased risk of infection in patients with psoriasis using some of the newer, more targeted medications compared to those taking methotrexate, a drug widely used since the 1960s as a first line treatment for moderate-to-severe psoriasis.

Higher weight increases risk of psoriasis
The higher a person's BMI, the greater the chance of getting psoriasis.

Lipid that aids normal skin turnover may help psoriasis
Topical application of the lipid phosphatidylglycerol, or PG, on a mouse model of psoriasis reduced inflammation as well as characteristic, raised skin lesions, they report in the Journal of Investigative Dermatology.

New insight into the mechanism of the drug against sclerosis and psoriasis
A multidisciplinary research team at Aarhus University has provided fundamental new insight into the mechanism of the medical drug dimethyl fumarate, which is the active component of important treatments for multiple sclerosis and psoriasis.

Read More: Psoriasis News and Psoriasis Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to